Corindus Vascular Robotics Inc

Corindus Vascular Robotics — Investor Presentation (January 2019)

19 slides from Corindus Vascular Robotics's investor presentation, Jan 4, 2019

  1. Slide 1: Precision Vascular Robotics

    Precision Vascular Robotics Corindus Vascular Robotics (CVRS) January 2019

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains “forward - looking statements” (as such term is defined in Section 27 A of the Securities Act of 1933 , as amended, and Section 21 E of the Securities Exchange Act of 1934 , as amended), and information relating to the company, that are based on

  3. Slide 3: Corindus: An Overview

    3 Corindus: An Overview FDA Clears CorPath GRX 2 nd generation technology for use in PCI Company Goes Public trading on NYSE as CVRS FDA Clears CorPath 200 for use in PCI Mayo Telestenting Partnership established to explore remote treatment FDA Clears 1 st Automated Robotic Move (RoR) first step tow

  4. Slide 4: Corindus' Robotic Technology

    • CorPath GRX cleared in late 2016 • Launched in 2017 • ~2,000 robotic CorPath GRX cassettes sold globally PCI Corindus’ Robotic Technology 4 1 CorPath Systems are not indicated for use in neuro interventions. • Ongoing clinical trials • Steering committee established in 2018 • Potential disruptor t

  5. Slide 5: Adding Value in PCI & Peripheral Across Key Stakeholders

    Adding Value in PCI & Peripheral Across Key Stakeholders 5 Paradigm Shift in Place Will Drive Adoption 1 Smilowitz N, et al. Robotic - Enhanced PCI Compared to the Traditional Manual Approach. J Invasive Cardiol , 2014;26(7):318 - 321. 2 Campbell PT, et al. The Impact of Precise Robotic Lesion Lengt

  6. Slide 6: Substantial Market Opportunity

    ~900K Stroke Incidence US 3 NEURO ~33% 4% Treated Substantial Market Opportunity 6 3+ M Procedures WW 1 (~900K US / ~2.2M OUS) PCI Over 2+ M Procedures WW 1 (~875K US / ~1.3M OUS) PERIPHERAL 11% CLI (BTK) Target Market : Expand TAM with remote access Target Market : US (Complex) / OUS (Simple / Comp

  7. Slide 7: Growing Interest Among Clinicians

    Growing Interest Among Clinicians Major activity in all vascular markets • Largest ever presence of robotics at TCT • Strong positive response to multiple live cases marked shift in sentiment • Performed the first live remote PCI “ telestenting ” procedure at a conference in a porcine model • Execut

  8. Slide 8: Robotics Integrates Into High Tech Care Models

    Robotics Integrates Into High Tech Care Models 8 Allow Procedures to be Performed Devices Robotics Imaging Artificial Intelligence Navigation Remote

  9. Slide 9: Procedural Automation

    Procedural Automation 9 • High percentage of procedure time is dedicated to wire manipulation • Varying skill levels among operators • Create algorithms based on techniques of highly skilled operators • Reduced procedure time may positively impact patient outcomes Problem Strategy New automated move

  10. Slide 10: Addressing Unmet Needs with Telerobotics

    Addressing Unmet Needs with Telerobotics Reduce time to treatment for emergent procedures such as STEMI and stroke The Problem Our Strategy Access to expertise & treatment is geographically limited Shortage of skilled specialists Incidence of STEMI & stroke on the rise due to aging patient populatio

  11. Slide 11: Remote Technology Development Achievements & Milestones

    Remote Technology Development Achievements & Milestones 11

  12. Slide 12: The Telerobotic Intervention Study

    The Telerobotic Intervention Study First - in - human remote coronary intervention December 4 th and 5 th , 2018 5 patients received successful PCI procedures with remote operator, Dr. Tejas Patel, at a distance of ~20 mi (32km) away 12

  13. Slide 13: Neurovascular Steering Committee / Milestones

    Neurovascular Steering Committee / Milestones 13 Aquilla S. Turk, D.O. Greenville Health System Ricardo A. Hanel , M.D. PhD Baptist Health System Tudor G. Jovin , M.D. University of Pittsburgh Medical Center J. Mocco , M.D. Mt. Sinai Hospital Vitor Mendes Pereria , M.D. Toronto Western Hospital Adna

  14. Slide 14: Stroke: Time to Treatment is Key

    Stroke: Time to Treatment is Key 14 Leading cause of death in the US ( 1 in 19 deaths) 1 1 American Heart Association. Heart Disease and Stroke Statistics 2012 Update At - a - Glance 1 minute ~2 million lost neurons = 5th 7+ million 2/3 stroke survivors 1 With a moderate - to - severe disability 1 A

  15. Slide 15: Remote Access Capabilities May Significantly Increase TAM

    ~900K U.S. Stroke Incidence 1 ~775K Ischemic Strokes ~335K Large Vessel Occlusion ~160K Salvageable Tissue ~35K Patients Treated Remote Access Capabilities May Significantly Increase TAM 15 • Treatment within 24 hours is critical • Yet only a fraction of patients (~35K) are treated due to: – Lack of

  16. Slide 16: Financials Snapshot

    9 16 23 33 37 41 45 0 5 10 15 20 25 30 35 40 45 50 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Financials Snapshot 16 Revenue $ 0.8 M $ 2.3 M $ 2.4 M $ 4.2 M $ 1.5 M $ 1.7 M $ 3.0 M 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 ~Cash balance of $29

  17. Slide 17: Clinical Catalysts: Next 12 Months

    Clinical Catalysts: Next 12 - 24 Months 17 Key Expected Milestones for Clinical Development Remote x Completed live remote PCI at TCT in Q3 2018 x First - in - human completed in December 2018 in India • First U.S. in - human remote case in 2019 • Approval of the next series of automated movements i

  18. Slide 18: Corindus Summary / Key Investment Thesis

    Corindus Summary / Key Investment Thesis 18 • Significant progress in technology development and clinical expansion is creating a burning platform for hospitals to build a robotic program • AI / automation and remote access have the potential to add significant value to hospitals, patients, and doct

  19. Slide 19: Precision Vascular Robotics

    Precision Vascular Robotics Corindus Vascular Robotics (CVRS) January 2019

Corindus Vascular Robotics — Investor Presentation (January 2019) on 6ix